WuXi XDC Cayman Inc (2268.HK)

Healthcare | Medical Diagnostics Research
Latest reporting period: 2026-04-07

Latest Quarter

2026-04-07

Revenue

$2.7B

Net Income

$746M

Operating Margin

28.4%

Free Cash Flow

-$788M

Debt / Assets

27.2%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for WuXi XDC Cayman Inc (2268.HK).
Income Statement (Quarterly) 2026-04-07 2025-06-30 2025-03-31 2024-06-30
Revenue 2,700,869,000 2,700,869,000 1,350,434,500 832,599,500
Cost of Revenue 1,725,622,000 1,725,622,000 862,811,000 564,934,000
Gross Profit 975,247,000 975,247,000 487,623,500 267,665,500
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 158,835,000 158,835,000 79,417,500 51,312,000
Operating Expenses 208,318,000 208,318,000 104,159,000 75,109,000
Operating Income 766,929,000 766,929,000 383,464,500 192,556,500
Interest Expense 0 0 0 0
Income Before Tax 867,150,000 867,150,000 433,575,000 280,858,000
Income Tax Expense 121,449,000 121,449,000 60,724,500 36,744,000
Net Income 745,701,000 745,701,000 372,850,500 244,114,000
Per Share
EPS 0.62 0.62 0.31 0.19
EPS Diluted 0.00 0.00 0.00 0.00